Addition of rapamycin to anti-CD3 antibody improves long-term glycaemia control in diabetic NOD mice

Non-Fc-binding Anti CD3 antibody has proven successful in reverting diabetes in the non-obese diabetes mouse model of type 1 diabetes and limited efficacy has been observed in human clinical trials. We hypothesized that addition of rapamycin, an mTOR inhibitor capable of inducing operational toleran...

Full description

Saved in:
Bibliographic Details
Published in:PloS one 2013-06, Vol.8 (6), p.e67189-e67189
Main Authors: Perl, Shira, Perlman, Jordan, Weitzel, R P, Phang, Oswald, Hsieh, Matthew M, Tisdale, John
Format: Article
Language:English
Subjects:
Analysis
Animals
Antibodies
Antibodies - therapeutic use
Biology
Blood
Blood glucose
Blood sugar
Bone marrow
Bone marrow transplantation
CD3 antigen
CD3 Complex - immunology
Clinical trials
Diabetes
Diabetes mellitus
Diabetes Mellitus, Experimental - complications
Diabetes Mellitus, Experimental - drug therapy
Drug dosages
Female
Glucose
Hematology
Humans
Hyperglycemia
Hyperglycemia - complications
Hyperglycemia - drug therapy
Immunological tolerance
Immunology
Injection
Lymphocytes
Medical research
Medicine
Mice
Mice, Inbred NOD
Obesity
Peptides
Peritoneum
Rapamycin
Rodents
Sickle cell disease
Sirolimus - pharmacology
Sirolimus - therapeutic use
TOR protein
Transplantation
Transplants & implants
Type 1 diabetes
Viral antibodies
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-c692t-190dd767490a2001914610e0b6d1586c271f0ee079a68a84b849490d559f3bc33
cites cdi_FETCH-LOGICAL-c692t-190dd767490a2001914610e0b6d1586c271f0ee079a68a84b849490d559f3bc33
container_end_page e67189
container_issue 6
container_start_page e67189
container_title PloS one
container_volume 8
creator Perl, Shira
Perlman, Jordan
Weitzel, R P
Phang, Oswald
Hsieh, Matthew M
Tisdale, John
description Non-Fc-binding Anti CD3 antibody has proven successful in reverting diabetes in the non-obese diabetes mouse model of type 1 diabetes and limited efficacy has been observed in human clinical trials. We hypothesized that addition of rapamycin, an mTOR inhibitor capable of inducing operational tolerance in allogeneic bone marrow transplantation, would result in improved diabetes reversal rates and overall glycemia. Seventy hyperglycemic non-obese diabetic mice were randomized to either a single injection of anti CD3 alone or a single injection of anti CD3 followed by 14 days of intra-peritoneal rapamycin. Mice were monitored for hyperglycemia and metabolic control. Mice treated with the combination of anti CD3 and rapamycin had similar rates of diabetes reversal compared to anti CD3 alone (25/35 vs. 22/35). Mice treated with anti CD3 plus rapamycin had a significant improvement in glycemia control as exhibited by lower blood glucose levels in response to an intra-peritoneal glucose challenge; average peak blood glucose levels 30 min post intra-peritoneal injection of 2 gr/kg glucose were 6.9 mmol/L in the anti CD3 plus rapamycin group vs. 10 mmo/L in the anti CD3 alone (P
doi_str_mv 10.1371/journal.pone.0067189
format article
fullrecord <record><control><sourceid>gale_plos_</sourceid><recordid>TN_cdi_plos_journals_1370901041</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A478010318</galeid><doaj_id>oai_doaj_org_article_470e357e8eee443d894e89877c3017e0</doaj_id><sourcerecordid>A478010318</sourcerecordid><originalsourceid>FETCH-LOGICAL-c692t-190dd767490a2001914610e0b6d1586c271f0ee079a68a84b849490d559f3bc33</originalsourceid><addsrcrecordid>eNqNk11r2zAUhs3YWLtu_2BshsHYLpxJliJLN4OQ7iNQFtjXrZClY0dBtlLLKcu_n9y4JR69GL6wkJ73lc57pCR5idEMkwJ_2Pp91yo32_kWZgixAnPxKDnHguQZyxF5fDI-S56FsEVoTjhjT5OznPCc5bk4T8zCGNtb36a-Sju1U81B2zbtfara3mbLS3I7KL05pLbZdf4GQup8W2c9dE1au4NW0FiVat_2nXdpFBurSuitTr-tL9PGaniePKmUC_Bi_F8kvz5_-rn8ml2tv6yWi6tMM5H3GRbImIIVVCCVI4QFpgwjQCUzeM6ZzgtcIQBUCMW44rTkVETWzOeiIqUm5CJ5ffTdOR_kGFCQMS4kEEYUR2J1JIxXW7nrbKO6g_TKytsJ39VSdfHoDiQtEJB5ARwAKCWGCwpc8KLQBOECUPT6OO62LxswGmIAyk1Mpyut3cja30jCBM6RiAbvRoPOX-8h9LKxQYNzqgW_H84tOCUEk6GyN_-gD1c3UrWKBdi28nFfPZjKBS14hAjmkZo9QMXPxEbGNkJl4_xE8H4iGFoNf_pa7UOQqx_f_59d_56yb0_YDSjXb4J3--E6hilIj6DufAgdVPchYzTUj-_SkMNjkONjiLJXpw26F93dfvIXD2gBjA</addsrcrecordid><sourcetype>Open Website</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1370901041</pqid></control><display><type>article</type><title>Addition of rapamycin to anti-CD3 antibody improves long-term glycaemia control in diabetic NOD mice</title><source>PubMed Central Free</source><source>ProQuest - Publicly Available Content Database</source><creator>Perl, Shira ; Perlman, Jordan ; Weitzel, R P ; Phang, Oswald ; Hsieh, Matthew M ; Tisdale, John</creator><contributor>von Herrath, Matthias G.</contributor><creatorcontrib>Perl, Shira ; Perlman, Jordan ; Weitzel, R P ; Phang, Oswald ; Hsieh, Matthew M ; Tisdale, John ; von Herrath, Matthias G.</creatorcontrib><description>Non-Fc-binding Anti CD3 antibody has proven successful in reverting diabetes in the non-obese diabetes mouse model of type 1 diabetes and limited efficacy has been observed in human clinical trials. We hypothesized that addition of rapamycin, an mTOR inhibitor capable of inducing operational tolerance in allogeneic bone marrow transplantation, would result in improved diabetes reversal rates and overall glycemia. Seventy hyperglycemic non-obese diabetic mice were randomized to either a single injection of anti CD3 alone or a single injection of anti CD3 followed by 14 days of intra-peritoneal rapamycin. Mice were monitored for hyperglycemia and metabolic control. Mice treated with the combination of anti CD3 and rapamycin had similar rates of diabetes reversal compared to anti CD3 alone (25/35 vs. 22/35). Mice treated with anti CD3 plus rapamycin had a significant improvement in glycemia control as exhibited by lower blood glucose levels in response to an intra-peritoneal glucose challenge; average peak blood glucose levels 30 min post intra-peritoneal injection of 2 gr/kg glucose were 6.9 mmol/L in the anti CD3 plus rapamycin group vs. 10 mmo/L in the anti CD3 alone (P&lt;0.05). The addition of rapamycin to anti CD3 results in significant improvement in glycaemia control in diabetic NOD mice.</description><identifier>ISSN: 1932-6203</identifier><identifier>EISSN: 1932-6203</identifier><identifier>DOI: 10.1371/journal.pone.0067189</identifier><identifier>PMID: 23826229</identifier><language>eng</language><publisher>United States: Public Library of Science</publisher><subject>Analysis ; Animals ; Antibodies ; Antibodies - therapeutic use ; Biology ; Blood ; Blood glucose ; Blood sugar ; Bone marrow ; Bone marrow transplantation ; CD3 antigen ; CD3 Complex - immunology ; Clinical trials ; Diabetes ; Diabetes mellitus ; Diabetes Mellitus, Experimental - complications ; Diabetes Mellitus, Experimental - drug therapy ; Drug dosages ; Female ; Glucose ; Hematology ; Humans ; Hyperglycemia ; Hyperglycemia - complications ; Hyperglycemia - drug therapy ; Immunological tolerance ; Immunology ; Injection ; Lymphocytes ; Medical research ; Medicine ; Mice ; Mice, Inbred NOD ; Obesity ; Peptides ; Peritoneum ; Rapamycin ; Rodents ; Sickle cell disease ; Sirolimus - pharmacology ; Sirolimus - therapeutic use ; TOR protein ; Transplantation ; Transplants &amp; implants ; Type 1 diabetes ; Viral antibodies</subject><ispartof>PloS one, 2013-06, Vol.8 (6), p.e67189-e67189</ispartof><rights>COPYRIGHT 2013 Public Library of Science</rights><rights>2013. This is an open-access article, free of all copyright, and may be freely reproduced, distributed, transmitted, modified, built upon, or otherwise used by anyone for any lawful purpose. The work is made available under the Creative Commons CC0 public domain dedication. Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><rights>2013</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c692t-190dd767490a2001914610e0b6d1586c271f0ee079a68a84b849490d559f3bc33</citedby><cites>FETCH-LOGICAL-c692t-190dd767490a2001914610e0b6d1586c271f0ee079a68a84b849490d559f3bc33</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.proquest.com/docview/1370901041/fulltextPDF?pq-origsite=primo$$EPDF$$P50$$Gproquest$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.proquest.com/docview/1370901041?pq-origsite=primo$$EHTML$$P50$$Gproquest$$Hfree_for_read</linktohtml><link.rule.ids>230,314,727,780,784,885,25753,27924,27925,37012,37013,44590,53791,53793,75126</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/23826229$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><contributor>von Herrath, Matthias G.</contributor><creatorcontrib>Perl, Shira</creatorcontrib><creatorcontrib>Perlman, Jordan</creatorcontrib><creatorcontrib>Weitzel, R P</creatorcontrib><creatorcontrib>Phang, Oswald</creatorcontrib><creatorcontrib>Hsieh, Matthew M</creatorcontrib><creatorcontrib>Tisdale, John</creatorcontrib><title>Addition of rapamycin to anti-CD3 antibody improves long-term glycaemia control in diabetic NOD mice</title><title>PloS one</title><addtitle>PLoS One</addtitle><description>Non-Fc-binding Anti CD3 antibody has proven successful in reverting diabetes in the non-obese diabetes mouse model of type 1 diabetes and limited efficacy has been observed in human clinical trials. We hypothesized that addition of rapamycin, an mTOR inhibitor capable of inducing operational tolerance in allogeneic bone marrow transplantation, would result in improved diabetes reversal rates and overall glycemia. Seventy hyperglycemic non-obese diabetic mice were randomized to either a single injection of anti CD3 alone or a single injection of anti CD3 followed by 14 days of intra-peritoneal rapamycin. Mice were monitored for hyperglycemia and metabolic control. Mice treated with the combination of anti CD3 and rapamycin had similar rates of diabetes reversal compared to anti CD3 alone (25/35 vs. 22/35). Mice treated with anti CD3 plus rapamycin had a significant improvement in glycemia control as exhibited by lower blood glucose levels in response to an intra-peritoneal glucose challenge; average peak blood glucose levels 30 min post intra-peritoneal injection of 2 gr/kg glucose were 6.9 mmol/L in the anti CD3 plus rapamycin group vs. 10 mmo/L in the anti CD3 alone (P&lt;0.05). The addition of rapamycin to anti CD3 results in significant improvement in glycaemia control in diabetic NOD mice.</description><subject>Analysis</subject><subject>Animals</subject><subject>Antibodies</subject><subject>Antibodies - therapeutic use</subject><subject>Biology</subject><subject>Blood</subject><subject>Blood glucose</subject><subject>Blood sugar</subject><subject>Bone marrow</subject><subject>Bone marrow transplantation</subject><subject>CD3 antigen</subject><subject>CD3 Complex - immunology</subject><subject>Clinical trials</subject><subject>Diabetes</subject><subject>Diabetes mellitus</subject><subject>Diabetes Mellitus, Experimental - complications</subject><subject>Diabetes Mellitus, Experimental - drug therapy</subject><subject>Drug dosages</subject><subject>Female</subject><subject>Glucose</subject><subject>Hematology</subject><subject>Humans</subject><subject>Hyperglycemia</subject><subject>Hyperglycemia - complications</subject><subject>Hyperglycemia - drug therapy</subject><subject>Immunological tolerance</subject><subject>Immunology</subject><subject>Injection</subject><subject>Lymphocytes</subject><subject>Medical research</subject><subject>Medicine</subject><subject>Mice</subject><subject>Mice, Inbred NOD</subject><subject>Obesity</subject><subject>Peptides</subject><subject>Peritoneum</subject><subject>Rapamycin</subject><subject>Rodents</subject><subject>Sickle cell disease</subject><subject>Sirolimus - pharmacology</subject><subject>Sirolimus - therapeutic use</subject><subject>TOR protein</subject><subject>Transplantation</subject><subject>Transplants &amp; implants</subject><subject>Type 1 diabetes</subject><subject>Viral antibodies</subject><issn>1932-6203</issn><issn>1932-6203</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2013</creationdate><recordtype>article</recordtype><sourceid>PIMPY</sourceid><sourceid>DOA</sourceid><recordid>eNqNk11r2zAUhs3YWLtu_2BshsHYLpxJliJLN4OQ7iNQFtjXrZClY0dBtlLLKcu_n9y4JR69GL6wkJ73lc57pCR5idEMkwJ_2Pp91yo32_kWZgixAnPxKDnHguQZyxF5fDI-S56FsEVoTjhjT5OznPCc5bk4T8zCGNtb36a-Sju1U81B2zbtfara3mbLS3I7KL05pLbZdf4GQup8W2c9dE1au4NW0FiVat_2nXdpFBurSuitTr-tL9PGaniePKmUC_Bi_F8kvz5_-rn8ml2tv6yWi6tMM5H3GRbImIIVVCCVI4QFpgwjQCUzeM6ZzgtcIQBUCMW44rTkVETWzOeiIqUm5CJ5ffTdOR_kGFCQMS4kEEYUR2J1JIxXW7nrbKO6g_TKytsJ39VSdfHoDiQtEJB5ARwAKCWGCwpc8KLQBOECUPT6OO62LxswGmIAyk1Mpyut3cja30jCBM6RiAbvRoPOX-8h9LKxQYNzqgW_H84tOCUEk6GyN_-gD1c3UrWKBdi28nFfPZjKBS14hAjmkZo9QMXPxEbGNkJl4_xE8H4iGFoNf_pa7UOQqx_f_59d_56yb0_YDSjXb4J3--E6hilIj6DufAgdVPchYzTUj-_SkMNjkONjiLJXpw26F93dfvIXD2gBjA</recordid><startdate>20130624</startdate><enddate>20130624</enddate><creator>Perl, Shira</creator><creator>Perlman, Jordan</creator><creator>Weitzel, R P</creator><creator>Phang, Oswald</creator><creator>Hsieh, Matthew M</creator><creator>Tisdale, John</creator><general>Public Library of Science</general><general>Public Library of Science (PLoS)</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>IOV</scope><scope>ISR</scope><scope>3V.</scope><scope>7QG</scope><scope>7QL</scope><scope>7QO</scope><scope>7RV</scope><scope>7SN</scope><scope>7SS</scope><scope>7T5</scope><scope>7TG</scope><scope>7TM</scope><scope>7U9</scope><scope>7X2</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8C1</scope><scope>8FD</scope><scope>8FE</scope><scope>8FG</scope><scope>8FH</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABJCF</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>ARAPS</scope><scope>ATCPS</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BGLVJ</scope><scope>BHPHI</scope><scope>C1K</scope><scope>CCPQU</scope><scope>D1I</scope><scope>DWQXO</scope><scope>FR3</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>H94</scope><scope>HCIFZ</scope><scope>K9.</scope><scope>KB.</scope><scope>KB0</scope><scope>KL.</scope><scope>L6V</scope><scope>LK8</scope><scope>M0K</scope><scope>M0S</scope><scope>M1P</scope><scope>M7N</scope><scope>M7P</scope><scope>M7S</scope><scope>NAPCQ</scope><scope>P5Z</scope><scope>P62</scope><scope>P64</scope><scope>PATMY</scope><scope>PDBOC</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PTHSS</scope><scope>PYCSY</scope><scope>RC3</scope><scope>7X8</scope><scope>5PM</scope><scope>DOA</scope></search><sort><creationdate>20130624</creationdate><title>Addition of rapamycin to anti-CD3 antibody improves long-term glycaemia control in diabetic NOD mice</title><author>Perl, Shira ; Perlman, Jordan ; Weitzel, R P ; Phang, Oswald ; Hsieh, Matthew M ; Tisdale, John</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c692t-190dd767490a2001914610e0b6d1586c271f0ee079a68a84b849490d559f3bc33</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2013</creationdate><topic>Analysis</topic><topic>Animals</topic><topic>Antibodies</topic><topic>Antibodies - therapeutic use</topic><topic>Biology</topic><topic>Blood</topic><topic>Blood glucose</topic><topic>Blood sugar</topic><topic>Bone marrow</topic><topic>Bone marrow transplantation</topic><topic>CD3 antigen</topic><topic>CD3 Complex - immunology</topic><topic>Clinical trials</topic><topic>Diabetes</topic><topic>Diabetes mellitus</topic><topic>Diabetes Mellitus, Experimental - complications</topic><topic>Diabetes Mellitus, Experimental - drug therapy</topic><topic>Drug dosages</topic><topic>Female</topic><topic>Glucose</topic><topic>Hematology</topic><topic>Humans</topic><topic>Hyperglycemia</topic><topic>Hyperglycemia - complications</topic><topic>Hyperglycemia - drug therapy</topic><topic>Immunological tolerance</topic><topic>Immunology</topic><topic>Injection</topic><topic>Lymphocytes</topic><topic>Medical research</topic><topic>Medicine</topic><topic>Mice</topic><topic>Mice, Inbred NOD</topic><topic>Obesity</topic><topic>Peptides</topic><topic>Peritoneum</topic><topic>Rapamycin</topic><topic>Rodents</topic><topic>Sickle cell disease</topic><topic>Sirolimus - pharmacology</topic><topic>Sirolimus - therapeutic use</topic><topic>TOR protein</topic><topic>Transplantation</topic><topic>Transplants &amp; implants</topic><topic>Type 1 diabetes</topic><topic>Viral antibodies</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Perl, Shira</creatorcontrib><creatorcontrib>Perlman, Jordan</creatorcontrib><creatorcontrib>Weitzel, R P</creatorcontrib><creatorcontrib>Phang, Oswald</creatorcontrib><creatorcontrib>Hsieh, Matthew M</creatorcontrib><creatorcontrib>Tisdale, John</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Gale_Opposing Viewpoints In Context</collection><collection>Gale In Context: Science</collection><collection>ProQuest Central (Corporate)</collection><collection>Animal Behavior Abstracts</collection><collection>Bacteriology Abstracts (Microbiology B)</collection><collection>Biotechnology Research Abstracts</collection><collection>Nursing &amp; Allied Health Database</collection><collection>Ecology Abstracts</collection><collection>Entomology Abstracts (Full archive)</collection><collection>Immunology Abstracts</collection><collection>Meteorological &amp; Geoastrophysical Abstracts</collection><collection>Nucleic Acids Abstracts</collection><collection>Virology and AIDS Abstracts</collection><collection>Agricultural Science Collection</collection><collection>Health &amp; Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Public Health Database</collection><collection>Technology Research Database</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Technology Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>Materials Science &amp; Engineering Collection</collection><collection>ProQuest Central (Alumni)</collection><collection>ProQuest Central</collection><collection>Advanced Technologies &amp; Aerospace Collection</collection><collection>Agricultural &amp; Environmental Science Collection</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>AUTh Library subscriptions: ProQuest Central</collection><collection>Technology Collection</collection><collection>Natural Science Collection</collection><collection>Environmental Sciences and Pollution Management</collection><collection>ProQuest One Community College</collection><collection>ProQuest Materials Science Collection</collection><collection>ProQuest Central Korea</collection><collection>Engineering Research Database</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>SciTech Premium Collection</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>Materials Science Database</collection><collection>Nursing &amp; Allied Health Database (Alumni Edition)</collection><collection>Meteorological &amp; Geoastrophysical Abstracts - Academic</collection><collection>ProQuest Engineering Collection</collection><collection>ProQuest Biological Science Collection</collection><collection>Agriculture Science Database</collection><collection>Health &amp; Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Algology Mycology and Protozoology Abstracts (Microbiology C)</collection><collection>Biological Science Database</collection><collection>Engineering Database</collection><collection>Nursing &amp; Allied Health Premium</collection><collection>Advanced Technologies &amp; Aerospace Database</collection><collection>ProQuest Advanced Technologies &amp; Aerospace Collection</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>Environmental Science Database</collection><collection>Materials Science Collection</collection><collection>ProQuest - Publicly Available Content Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>Engineering Collection</collection><collection>Environmental Science Collection</collection><collection>Genetics Abstracts</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><collection>Directory of Open Access Journals (Open Access)</collection><jtitle>PloS one</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Perl, Shira</au><au>Perlman, Jordan</au><au>Weitzel, R P</au><au>Phang, Oswald</au><au>Hsieh, Matthew M</au><au>Tisdale, John</au><au>von Herrath, Matthias G.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Addition of rapamycin to anti-CD3 antibody improves long-term glycaemia control in diabetic NOD mice</atitle><jtitle>PloS one</jtitle><addtitle>PLoS One</addtitle><date>2013-06-24</date><risdate>2013</risdate><volume>8</volume><issue>6</issue><spage>e67189</spage><epage>e67189</epage><pages>e67189-e67189</pages><issn>1932-6203</issn><eissn>1932-6203</eissn><abstract>Non-Fc-binding Anti CD3 antibody has proven successful in reverting diabetes in the non-obese diabetes mouse model of type 1 diabetes and limited efficacy has been observed in human clinical trials. We hypothesized that addition of rapamycin, an mTOR inhibitor capable of inducing operational tolerance in allogeneic bone marrow transplantation, would result in improved diabetes reversal rates and overall glycemia. Seventy hyperglycemic non-obese diabetic mice were randomized to either a single injection of anti CD3 alone or a single injection of anti CD3 followed by 14 days of intra-peritoneal rapamycin. Mice were monitored for hyperglycemia and metabolic control. Mice treated with the combination of anti CD3 and rapamycin had similar rates of diabetes reversal compared to anti CD3 alone (25/35 vs. 22/35). Mice treated with anti CD3 plus rapamycin had a significant improvement in glycemia control as exhibited by lower blood glucose levels in response to an intra-peritoneal glucose challenge; average peak blood glucose levels 30 min post intra-peritoneal injection of 2 gr/kg glucose were 6.9 mmol/L in the anti CD3 plus rapamycin group vs. 10 mmo/L in the anti CD3 alone (P&lt;0.05). The addition of rapamycin to anti CD3 results in significant improvement in glycaemia control in diabetic NOD mice.</abstract><cop>United States</cop><pub>Public Library of Science</pub><pmid>23826229</pmid><doi>10.1371/journal.pone.0067189</doi><tpages>e67189</tpages><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 1932-6203
ispartof PloS one, 2013-06, Vol.8 (6), p.e67189-e67189
issn 1932-6203
1932-6203
language eng
recordid cdi_plos_journals_1370901041
source PubMed Central Free; ProQuest - Publicly Available Content Database
subjects Analysis
Animals
Antibodies
Antibodies - therapeutic use
Biology
Blood
Blood glucose
Blood sugar
Bone marrow
Bone marrow transplantation
CD3 antigen
CD3 Complex - immunology
Clinical trials
Diabetes
Diabetes mellitus
Diabetes Mellitus, Experimental - complications
Diabetes Mellitus, Experimental - drug therapy
Drug dosages
Female
Glucose
Hematology
Humans
Hyperglycemia
Hyperglycemia - complications
Hyperglycemia - drug therapy
Immunological tolerance
Immunology
Injection
Lymphocytes
Medical research
Medicine
Mice
Mice, Inbred NOD
Obesity
Peptides
Peritoneum
Rapamycin
Rodents
Sickle cell disease
Sirolimus - pharmacology
Sirolimus - therapeutic use
TOR protein
Transplantation
Transplants & implants
Type 1 diabetes
Viral antibodies
title Addition of rapamycin to anti-CD3 antibody improves long-term glycaemia control in diabetic NOD mice
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-04T10%3A50%3A30IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_plos_&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Addition%20of%20rapamycin%20to%20anti-CD3%20antibody%20improves%20long-term%20glycaemia%20control%20in%20diabetic%20NOD%20mice&rft.jtitle=PloS%20one&rft.au=Perl,%20Shira&rft.date=2013-06-24&rft.volume=8&rft.issue=6&rft.spage=e67189&rft.epage=e67189&rft.pages=e67189-e67189&rft.issn=1932-6203&rft.eissn=1932-6203&rft_id=info:doi/10.1371/journal.pone.0067189&rft_dat=%3Cgale_plos_%3EA478010318%3C/gale_plos_%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c692t-190dd767490a2001914610e0b6d1586c271f0ee079a68a84b849490d559f3bc33%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=1370901041&rft_id=info:pmid/23826229&rft_galeid=A478010318&rfr_iscdi=true